美国340B药品定价计划下院外药房管理的经验与启示

贾月明; 姜来; 吕兰婷

doi:10.6039/j.issn.1001-0408.2023.08.01

您当前的位置：

首页 >

文章列表页 >

美国340B药品定价计划下院外药房管理的经验与启示

药事管理 | 更新时间：2023-04-25

- 美国340B药品定价计划下院外药房管理的经验与启示
- Experience and enlightenment of out-of-hospital pharmacy management under the 340B drug pricing program in the United States
- 中国药房 2023年34卷第8期页码：897-901
- 作者机构：
  
  1.北京明德医院药剂科，北京　100015
  2.中国人民大学卫生技术评估与医药政策研究中心，北京　100872
  3.中国人民大学公共管理学院，北京　100872
- 作者简介：
  
  主管药师，硕士。研究方向：公共管理。E-mail：Janelunar@126.com
  副教授，硕士生导师，博士。研究方向：卫生经济学在卫生政策制定、决策分析模型、卫生资源管理中的应用。E-mail：lanting.lu@ruc.edu.cn
- 基金信息：
  
  国家社科基金重大项目(22ZDA096);中国人民大学公共健康与卫生疾控跨学科交叉平台资金项目(2021PDPC)
- DOI：10.6039/j.issn.1001-0408.2023.08.01
  中图分类号： R95
- 纸质出版日期：2023-04-30，
  
  收稿日期：2022-10-12，
  
  修回日期：2023-04-03，
扫描看全文
贾月明,姜来,吕兰婷.美国340B药品定价计划下院外药房管理的经验与启示 ^Δ[J].中国药房,2023,34(08):897-901.

JIA Yueming,JIANG Lai,LYU Lanting.Experience and enlightenment of out-of-hospital pharmacy management under the 340B drug pricing program in the United States[J].ZHONGGUO YAOFANG,2023,34(08):897-901.
贾月明,姜来,吕兰婷.美国340B药品定价计划下院外药房管理的经验与启示 ^Δ[J].中国药房,2023,34(08):897-901. DOI： 10.6039/j.issn.1001-0408.2023.08.01.

JIA Yueming,JIANG Lai,LYU Lanting.Experience and enlightenment of out-of-hospital pharmacy management under the 340B drug pricing program in the United States[J].ZHONGGUO YAOFANG,2023,34(08):897-901. DOI： 10.6039/j.issn.1001-0408.2023.08.01.

摘要

目的

借鉴美国340B药品定价计划（简称340B计划）经验，为优化我国药品“双通道”政策下定点零售药店的运行与管理提供参考。

方法

通过梳理美国实施340B计划下院外药房的实施现状，总结该计划下院外药房管理的经验，提出我国药品“双通道”政策下定点零售药店的管理思路和可能遇到的问题。结果与

结论

340B计划下的院外药房相对于医疗机构而言缺乏充分的患者基本信息和医保状态信息，易出现重复折扣和药品转移的问题；同时由于院外药房脱离了医疗机构内药品使用的管理和限制，加上销售药品带来的经济激励，使得美国340B计划面临高额医疗卫生费用支出与院外药房逆向选择风险。建议我国在进行药品“双通道”政策定点零售药店建设时，应该明确定点零售药店遴选标准，增强医疗机构和定点零售药店的财务透明度，建立科学的处方流转机制，加强参保患者与处方的审核以及认证管理，健全监督管理机制，同时将定点零售药店的药品销售情况合理纳入医疗机构用药管理中，从而实现药品可及的同时不滥用，科学控费。

Abstract

OBJECTIVE

To learn from 340B drug pricing program （short for 340B program） in the United States， and provide reference for optimizing the operation and management of designated retail pharmacies under the “dual channel” policy in China.

METHODS

The status quos of the implementation of out-of-hospital pharmacies under the 340B program in the United States was reviewed to summarize the experience of the management of out-of-hospital pharmacies under the program in the United States， and to propose thoughts of management and possible problems for designated retail pharmacies under the “dual channel” policy in China.

RESULTS &

CONCLUSIONS

Out-of-hospital pharmacies under the 340B program lacked sufficient basic information and medical insurance status of patients compared to medical institutions， which easily led to duplicate discounts and drug diversion issues. Due to the separation of out-of-hospital pharmacies from the management and restrictions on the use of drugs in medical institutions， coupled with the economic incentives brought by the sale of drugs， the 340B program in the United States faced high medical expenditure and adverse selection risks for out-of-hospital pharmacies. In this regard， when China is carrying out the construction of designated retail pharmacies under the “dual channel” policy， it is necessary to clarify the selection criteria for designated retail pharmacies， enhance the financial transparency of medical institutions and designated retail pharmacies， establish a scientific prescription circulation mechanism， strengthen the review and certification of insured patients and prescriptions， and improve the supervision and management mechanism. Meanwhile， the drug sales situation of designated retail pharmacies should be reasonably incorporated into the drug use management of medical institutions， so as to achieve the availability of drugs without abuse， and effectively control costs.

关键词

340B药品定价计划双通道定点零售药店重复折扣药品转移

Keywords

dual-channeldesignated retail pharmacyduplicate discountsdrug diversion

references

张博，丁锦希，陈烨，等.国家医保谈判药品“双通道”政策动因与实施模式[J].世界临床药物，2021，42（9）：709-716.

FEIN A J. Challenges for managed care from 340B contract pharmacies[J]. J Manag Care Spec Pharm，2016，22（3）：197-203.

KAREN M.The 340B drug pricing program：background，ongoing challenges and recent developments[EB/OL].（2021-10-13）[2022-06-04]. https：//healthpolicy.usc.edu/research/the-340b-drug-pricing-program-background-on-going-challenges-and-recent-developments/https://healthpolicy.usc.edu/research/the-340b-drug-pricing-program-background-on-going-challenges-and-recent-developments/.

FEIN A J. Exclusive：the 340B program soared to $38 billion in 2020-up 27% vs. 2019[EB/OL].（2021-06-16）[2022- 06-04]. https：//www.drugchannels.net/2021/06/exclusive-340b-program-soared-to-38.htmlhttps://www.drugchannels.net/2021/06/exclusive-340b-program-soared-to-38.html.

CLARK B L，HOU J，CHOU C H，et al. The 340B discount program：outpatient prescription dispensing patterns through contract pharmacies in 2012[J]. Health Aff（Millwood），2014，33（11）：2012-2017.

MEDPAC. Overview of the 340B drug pricing program[EB/OL].（2015-05）[2022-05-22]. https：//www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/de-fault-source/reports/may-2015-report-to-the-congress-over-view-of-the-340b-drug-pricing-program.pdfhttps://www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/de-fault-source/reports/may-2015-report-to-the-congress-over-view-of-the-340b-drug-pricing-program.pdf.

TARA O. Market distortions caused by the 340B prescription drug program[EB/OL].（2017-11-28）[2022-06-08]. https：//www.americanactionforum.org/research/340bmarketdistortions/#_edn22https://www.americanactionforum.org/research/340bmarketdistortions/#_edn22.

E&C. Review of the 340B drug pricing program[EB/OL].（2018-01-10）[2022-05-25]. https：//republicans-energycom-merce.house.gov/wp-content/uploads/2018/01/20180110-Review_of_the_340B_Drug_Pricing_Program.pdf#：~：text= According%20to%20the%201992%20Hou-se%20Report%20accompanying%20thehttps://republicans-energycom-merce.house.gov/wp-content/uploads/2018/01/20180110-Review_of_the_340B_Drug_Pricing_Program.pdf#:~:text=According%20to%20the%201992%20Hou-se%20Report%20accompanying%20the，reduced%20dr-ug%20pri-ces%20offered%20under%20the%20340B%20program.

HRSA. Duplicate discount prohibition[EB/OL].（2020-07）[2022-06-08]. https：//www.hrsa.gov/opa/program-require-ments/medicaid-exclusion/index.htmlhttps://www.hrsa.gov/opa/program-require-ments/medicaid-exclusion/index.html.

MEDPAC. The 340B drug pricing program and medicaid drug rebate program：how they interact[EB/OL]. （2018-05）[2022-05-18]. https：//www.macpac.gov/wp-content/uploads/2018/05/340B-Drug-Pricing-Program-and-Medi-caid-Drug-Rebate-Program-How-They-Interact.pdf#：~：te-xt=The%20Medicaid%20Drug%20Rebate%20Program%20and%20the%20340Bhttps://www.macpac.gov/wp-content/uploads/2018/05/340B-Drug-Pricing-Program-and-Medi-caid-Drug-Rebate-Program-How-They-Interact.pdf#:~:te-xt=The%20Medicaid%20Drug%20Rebate%20Program%20and%20the%20340B，Medicaid%20programs%20wi-th%20regard%20to%20340B%20%28NAMD%2020-15%29.

SARAH C，SUSAN E B，DEBBIE M C. 340B program self-monitoring：diversion and duplicate discounts[EB/OL].（2021-08-06）[2022-06-17]. https：//www.crowe.com/insights/healthcare-connection/340b-program-self-monito-ring-diversion-and-duplicate-discountshttps://www.crowe.com/insights/healthcare-connection/340b-program-self-monito-ring-diversion-and-duplicate-discounts.

GERLACH J，MCSWEENEY S，SWEARINGEN A，et al. Examining the benefits of the 340B drug discount program[J]. Health Care Manag（Frederick），2018，37（3）：225-231.

CONTI R M，BACH P B. The 340B drug discount program：hospitals generate profits by expanding to reach more affluent communities[J]. Health Aff（Millwood），2014，30（10）：1786-1792.

陈一，丁锦希，陈烨，等.“双通道”框架下的DTP药房管理模式研究[J].世界临床药物，2021，42（9）：725-733.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据